ADC Therapeutics to Join H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ

ADC Therapeutics SA, a leader in the field of antibody drug conjugates (ADCs), has revealed the participation of its CEO, Ameet Mallik, in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ. The event is scheduled for Monday, May 20, 2024, at 2:00 p.m. ET. Attendees and interested parties can access a live webcast of the presentation through the Events & Presentations page in the Investors section of ADC Therapeutics’ website. Additionally, a replay of the webcast will be available for about 30 days following the presentation.

ADC Therapeutics is recognized globally as a commercial-stage leader in the development of ADCs, which are used to treat various hematologic and solid tumors. Their innovative approach aims to revolutionize the treatment protocols for patients suffering from these severe diseases. The company’s flagship product, ZYNLONTA (loncastuximab tesirine-lpyl), which targets CD19, has gained accelerated approval from the FDA and conditional approval from the European Commission. This approval is specifically for patients with relapsed or refractory diffuse large B-cell lymphoma who have undergone at least two prior systemic treatments.

ZYNLONTA is not only approved for standalone use but is also being explored in combination with other therapeutic agents and for use in earlier stages of therapy. Beyond ZYNLONTA, ADC Therapeutics has a robust pipeline with multiple ADCs in various stages of clinical and preclinical development, signaling their ongoing commitment to advancing cancer treatment.

The company operates out of Lausanne, Switzerland, within the Biopôle life sciences campus, and maintains additional operations in London and New Jersey. This geographic diversity supports their global reach and capabilities in research, development, and commercialization of their ADC technology.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!